Peer Reviewed Publication , Human ADME

ADME of opicapone in human healthy volunteers

16 June 2022
Overview
Study Paper: Absorption, metabolism and excretion of opicapone in human healthy volunteers

Absorption, metabolism and excretion of opicapone in human healthy volunteers Aims: The absorption, metabolism and excretion of opicapone (2,5-dichloro- 3-(5-[3,4-dihydroxy-5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide), a selective catechol-O-methyltransferase inhibitor, were investigated. Methods: Plasma, urine and faeces were collected from healthy male subjects following a single oral dose of 100 mg [14C]-opicapone. The mass balance of [14C]-opicapone and metabolic profile were evaluated.

Br J Clin Pharmacol. 2022;1–12.

Download
Date
16 June 2022

Your challenges. Our solutions.

Learn more about our expertise in human ADME studies.

Quotient Sciences Logo
Human ADME, Regulatory, Dr. Adam Robinson-Miller

Assessing the Impact of the Approved FDA Guidance on Human Mass Balance Studies: How ADME programs will proceed in 2024 and beyond

By: Dr. Adam Robinson-Miller Read More
Get in touch
Humanity can't afford to wait, so neither can we.